Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kaken Pharmaceutical Co's total inventories for the quarter that ended in Mar. 2026 was 円19,115 Mil. Kaken Pharmaceutical Co's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was 円19,882 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Kaken Pharmaceutical Co's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was 円1,167.11.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Kaken Pharmaceutical Co's Days Inventory for the
three
months ended in Mar. 2026 was 179.73.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Kaken Pharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2026 was 0.51.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kaken Pharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 1.03.
Kaken Pharmaceutical Co (TSE:4521) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Kaken Pharmaceutical Co's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Kaken Pharmaceutical Co's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Kaken Pharmaceutical Co Total Inventories Related Terms
Kaken Pharmaceutical Co Total Inventories Historical Data
* Premium members only.
The historical data trend for Kaken Pharmaceutical Co's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaken Pharmaceutical Co Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
What does a Total Inventories of 円19,115 Mil mean?
Kaken Pharmaceutical Co (TSE:4521) has a Total Inventories of 円19,115 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Kaken Pharmaceutical Co and its competitors.
Is Kaken Pharmaceutical Co's Total Inventories too high?
Kaken Pharmaceutical Co's current Total Inventories is 円19,115 Mil. Overall, Kaken Pharmaceutical Co has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Kaken Pharmaceutical Co's Total Inventories compare to ZTS and UTHR?
Kaken Pharmaceutical Co's Total Inventories of 円19,115 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Drug Manufacturers company?
A good Total Inventories depends on the Drug Manufacturers industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Kaken Pharmaceutical Co and its competitors. Kaken Pharmaceutical Co's current Total Inventories is 円19,115 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaken Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co (TSE:4521) is currently considered Fairly Valued. The stock's GF Value™ is 円3,775.44, compared to a current price of 円3,900.00 — trading 3.3% above its estimated fair value. The current Total Inventories is 円19,115 Mil. Kaken Pharmaceutical Co's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Kaken Pharmaceutical Co (TSE:4521), the current Total Inventories is 円19,115 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kaken Pharmaceutical Co (TSE:4521) Overvalued in 2026?
Based on GuruFocus' analysis, Kaken Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,900.00 is trading 3.3% above its estimated GF Value™ of 円3,775.44.
GuruFocus considers Kaken Pharmaceutical Co to be Fairly Valued.
Key valuation signals for TSE:4521:
Total Inventories: 円19,115 Mil
GF Value™: 円3,775.44 vs. price of 円3,900.00 (3.3% above fair value)
No single metric tells the full story. See the TSE:4521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kaken Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. The company organizes its segments between pharmaceutical and real estate activities. The pharmaceutical segment consists of pharmaceutical drugs, medical devices, and agrochemicals. In the real estate segment, the majority of revenue is generated through commercial facility rental fees. Sales in Japan constitute more than 90% of revenue. Kaken considers merger and acquisition investment to be a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
69GF Score
Get the complete analysis for TSE:4521
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4521 has been successfully added to your 
